Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02391051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

Study acronym: FOKAL-BT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 11, 2017 (before its estimated December 2019 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 2017 to Dec 2019
    • Study completion date: Jul 2027 to Dec 2029
    v4
  2. 2 versions Re-verified since Dec 2, 2015, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Trial Details
NCT Number NCT02391051
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov